Interest of Auriculotherapy in the Management of Chronic Insomnia

Chronic Insomnia Clinical Trial

— AURICULO-DODO  

Official title:

Interest of Auriculotherapy in the Management of Chronic Insomnia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04471168
• Other study ID #: 2018_0107
• Status: Recruiting
• Phase: N/A
• Start date: October 14, 2020
• Est. completion date: October 2023

Study information

• Verified date: June 2023
• Source: Hopital Foch
• Contact: Mireille Michel-Cherqui, MD
• Phone: +33(0)146252985
• Email: m.michel-cherqui[@]hopital-foch.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of the study is to show that auriculotherapy is effective in the treatment of chronic insomnia.

Description:

Chronic insomnia affects a significant proportion of the French population with an estimated prevalence between 15% and 20%.

This disease is mainly managed by general practitioners for whom benzodiazepines and Z-drugs (zopiclone, zolpidem) represent the first-line treatment. The french health authorities recommend limiting the consumption of these molecules to 2 to 4 weeks taking into account their possible undesirable effects (eg memory impairment, in the elderly, road accident) as well as the risk of tolerance and addiction. However, it appears that a majority of the patients concerned become chronic consumers.

The investigators propose to assess cryo-auriculotherapy in the treatment of chronic insomnia.

The population studied will consist of patients with chronic insomnia, whose diagnosis has been made according to the definition in the diagnostic and statistical manual of mental disorders (DSM-5), and followed up in an outpatient clinic at Foch Hospital or in one of the participating centers.

Half of the patients will be treated with cryo-auriculotherapy (use of a device with nitrous oxide) and compared with control patients who will have the same treatment visits involving a sham device (device without nitrous oxide).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 72
• Est. completion date: October 2023
• Est. primary completion date: October 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Suffering from chronic insomnia as defined in the diagnostic and statistical manual of mental disorders (DSM-5)

• Score = 15 on the Insomnia Severity Index (ISI) questionnaire;

• Covered by a national healthcare insurance

• Consent form signed

Exclusion Criteria:

• Pregnant woman or pregnancy planned for the duration of the study;

• Regular night work or shift work / reversal of sleep patterns;

• Trans meridian travel during the previous month or planned during the study period;

• Unstable or untreated psychiatric disorder including severe depression, severe addiction, unbalanced bipolar disorder;

• Taking insomnia-inducing drugs (eg Corticoids);

• Hypnotic treatment or antidepressant treatment with hypnotic aim introduced since less than 4 weeks or with change dating back less than 4 weeks;

• Presence of organic comorbidities which may be responsible for sleep disorders (SAS and restless legs syndrome): (STOP-BANG) score = 5;

• History of central neurological disorders or progressive brain injury;

• Contraindication to the use of auriculotherapy (lesion or infection of the pinna) by cryotherapy (skin scarring disorder, risk of hypo or hyperpigmentation);

• Treatment by auriculotherapy or acupuncture in this indication in the previous 12 months;

• Previous treatment with cryo-auriculotherapy

• Having started in the month preceding the first auriculotherapy session, any new treatment likely to interfere with the study: specific drug treatment (antidepressant, morphine or anticonvulsant) or complementary therapy (psychological care, physiotherapy, balneotherapy, etc.).

• Difficulty complying with the treatment, questionnaire or study protocol.

• Be deprived of liberty or under guardianship.

Related Conditions & MeSH terms

• Chronic Insomnia
• Sleep Initiation and Maintenance Disorders

Intervention

Device:
• Cryo-Auriculotherapy
3 sessions of cryo-auriculotherapy with device with nitrous oxyde on 10 auricular points at one month intervals.
• Sham comparator
3 sessions of cryo-auriculotherapy with device without nitrous oxyde on 10 auricular points at one month intervals.

Locations

Country	Name	City	State
France	Espace Santé Simone Veil	Issy-les-Moulineaux	Hauts De Seine
France	Cabinet Médical Nouvelle France	Le Chesnay	Yvelines
France	Cabinet de l'Olivier	Montigny-le-Bretonneux	Yvelines
France	Hopital Foch	Suresnes

Sponsors (1)

Lead Sponsor	Collaborator
Hopital Foch

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with improvement of insomnia after 3 month of treatment (Real Auriculotherapy group compared to Sham Auriculotherapy group)	Comparison of the evolution of the score of the Insomnia Severity Index (7-item self-report questionnaire assessing the nature, severity, and impact of insomnia).; Total score categories: 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe); The improvement will be defined as a decrease in the score of the questionnaire by 3 points between Day 90 and Day 0.; A comparison of the improvement according to the 2 arms will be made.	3 months
Secondary	Evolution of sleep quality and sleep disorders	Specific questionnaire Pittsburgh Sleep Quality Index (PSQI)at inclusion and at 3 months (1 month post-treatment).; Seven component scores are derived, each scored 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range 0 to 21).; Higher scores indicate worse sleep quality.	3 months
Secondary	Evolution of drug consumption linked to chronic insomnia	Drugs used to control chronic insomnia will be collected from the inclusion to 3 months (1 month post-treatment)	3 months
Secondary	Evolution and Anxiety and depression	Hospital Anxiety and Depression questionnaire will be used at inclusion and at 3 months post-treatment.; There are seven questions related to anxiety (total A) and seven others related to the depressive dimension (total D), allowing thus obtaining two scores (maximum score of each score = 21).; Higher score indicates a certain symptomatology : 7 or less: absence of symptoms; 8 to 10: doubtful symptomatology; 11 and more: certain symptomatology.	3 months
Secondary	Evolution of quality of life	EuroQoL five Dimension questionnaire at inclusion and at 3 months post-treatment. This questionnaire is designed for the patient to judge the impact of his state of health on his quality of life according to 5 dimensions (mobility, personal autonomy, daily activities, pain / discomfort and anxiety / depression). Each item has 3 response levels (1, 2 and 3) and the combination of the five digits will represent the patient's state of health. It is supplemented by a quality of life thermometer graduated from 0 (worst quality of life) to 100 (best quality of life).	3 months
Secondary	Overall patient impression	Patient Global Impression of Change questionnaire (PGIC) used at the end of the follow-up.; This scale evaluates all aspects of patients' health and assesses if there has been an improvement or decline in clinical status with a seven-point single-item scale ranging from 'very much worse' to 'very much improved'	3 months
Secondary	Willingness of the patient to continue treatment	Patient will be asked at the end of the study if they want to pursue the treatment	3 months
Secondary	Tolerance of cryotherapy auriculotherapy treatment.	The presence or absence of adverse events attributed to the treatment of auriculotherapy by the patient.	3 months